LWAM
AVDL

Legacy Wealth Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Legacy Wealth Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,000
Closed -$119K – 336
2023
Q1 		$119K Hold
13,000
– – 0.04% 329
2022
Q4 		$93.1K Hold
13,000
– – 0.04% 330
2022
Q3 		$65K Hold
13,000
– – 0.03% 312
2022
Q2 		$32K Hold
13,000
– – 0.01% 317
2022
Q1 		$89K Hold
13,000
– – 0.03% 315
2021
Q4 		$105K Hold
13,000
– – 0.04% 309
2021
Q3 		$127K Hold
13,000
– – 0.06% 287
2021
Q2 		$87K Buy
+13,000
New +$103K 0.04% 301

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Legacy Wealth Asset Management's AVDL Position: Q2 2023 in Review

Legacy Wealth Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 13,000 shares — an estimated $119K sold.

Legacy Wealth Asset Management first reported a position in AVDL in Q2 2021 and held it in 8 quarters. The position peaked at $127K in Q3 2021. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • Legacy Wealth Asset Management reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Legacy Wealth Asset Management sold 13,000 Avadel Pharmaceuticals shares in Q2 2023, an estimated $119K.
  • Legacy Wealth Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Legacy Wealth Asset Management's Avadel Pharmaceuticals position peaked at $127K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on Legacy Wealth Asset Management's 13F filing for Q2 2023, filed 4 Aug 2023.